Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerd Geisslinger

Showing results (1-10 of 441) with videos related to

Pageof 45
Sort By:
Drug Discovery Today|October 22, 2011
Low-dose drug combinations along molecular pathways could maximize therapeutic effectiveness while minimizing collateral adverse effectsJörn Lötsch, Gerd Geisslinger
Pharmazie in Unserer Zeit|April 30, 2002
[Current post-marketing information. Effects and adverse effects of celecoxib]Helmut Schmidt, Gerd Geisslinger
Pain|February 14, 2006
Current evidence for a genetic modulation of the response to analgesicsJörn Lötsch, Gerd Geisslinger
British Journal of Pharmacology|October 15, 2010
Pharmacogenetics of new analgesicsJörn Lötsch, Gerd Geisslinger
Naunyn-Schmiedeberg'S Archives of Pharmacology|April 6, 2006
Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Irmgard Tegeder, Gerd Geisslinger
Expert Review of Proteomics|April 12, 2013
Proteomics and NF-κB: an updateEllen Niederberger, Gerd Geisslinger
Trends in Pharmacological Sciences|July 4, 2006
Is mPGES-1 a promising target for pain therapy?Klaus Scholich, Gerd Geisslinger
Trends in Pharmacological Sciences|May 21, 2010
A critical appraisal of human genotyping for pain therapyJörn Lötsch, Gerd Geisslinger
Pharmacological Reviews|August 20, 2004
Opioids as modulators of cell death and survival--unraveling mechanisms and revealing new indicationsIrmgard Tegeder, Gerd Geisslinger
Clinical Pharmacology and Therapeutics|July 4, 2006
Misestimating the role of an active metabolite when modeling the effects after administration of the parent compound onlyJörn Lötsch, Gerd Geisslinger
Pageof 45

Showing results (1-10 of 441) with videos related to

Sort By:
Pageof 45
Drug Discovery Today|October 22, 2011
Low-dose drug combinations along molecular pathways could maximize therapeutic effectiveness while minimizing collateral adverse effectsJörn Lötsch, Gerd Geisslinger
Pharmazie in Unserer Zeit|April 30, 2002
[Current post-marketing information. Effects and adverse effects of celecoxib]Helmut Schmidt, Gerd Geisslinger
Pain|February 14, 2006
Current evidence for a genetic modulation of the response to analgesicsJörn Lötsch, Gerd Geisslinger
British Journal of Pharmacology|October 15, 2010
Pharmacogenetics of new analgesicsJörn Lötsch, Gerd Geisslinger
Naunyn-Schmiedeberg'S Archives of Pharmacology|April 6, 2006
Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Irmgard Tegeder, Gerd Geisslinger
Expert Review of Proteomics|April 12, 2013
Proteomics and NF-κB: an updateEllen Niederberger, Gerd Geisslinger
Trends in Pharmacological Sciences|July 4, 2006
Is mPGES-1 a promising target for pain therapy?Klaus Scholich, Gerd Geisslinger
Trends in Pharmacological Sciences|May 21, 2010
A critical appraisal of human genotyping for pain therapyJörn Lötsch, Gerd Geisslinger
Pharmacological Reviews|August 20, 2004
Opioids as modulators of cell death and survival--unraveling mechanisms and revealing new indicationsIrmgard Tegeder, Gerd Geisslinger
Clinical Pharmacology and Therapeutics|July 4, 2006
Misestimating the role of an active metabolite when modeling the effects after administration of the parent compound onlyJörn Lötsch, Gerd Geisslinger
Pageof 45